Hysplex
Hysplex is focused upon the development of novel PARP inhibitors that could provide breakthrough treatments to cancer patients with defective DNA damage repair pathways, as well as patients afflicted with certain neuroinflammatory conditions, such as Parkinson’s disease.
Active Portfolio Company